Journal of diabetes and its complications最新文献

{"title":"Effect of colchicine on platelet aggregation in patients with type 2 diabetes: Results from a randomized placebo-controlled trial","authors":"Jonathan M. Baier ,&nbsp;Kristian L. Funck ,&nbsp;Liv Vernstrøm ,&nbsp;Søren Gullaksen ,&nbsp;Per L. Poulsen ,&nbsp;Esben Laugesen","doi":"10.1016/j.jdiacomp.2025.109141","DOIUrl":"10.1016/j.jdiacomp.2025.109141","url":null,"abstract":"<div><h3>Background</h3><div>Patients with type 2 diabetes face an increased risk of cardiovascular disease (CVD), partly due to a prothrombotic state with increased platelet reactivity. Colchicine, an anti-inflammatory drug, has shown promise in reducing cardiovascular events, but its effects on platelet function remain unclear. This trial evaluated the effect of low-dose colchicine on platelet aggregation and platelet activation indices in patients with type 2 diabetes.</div></div><div><h3>Methods</h3><div>In this double-blind, randomized, placebo-controlled trial, 100 participants with type 2 diabetes and previous CVD or a least one cardiovascular risk factor were randomized in a 1:1 ratio to receive either colchicine (0.5 mg/day) or placebo for 26 weeks. Platelet aggregation was assessed using multiple electrode aggregometry expressed as aggregation units (AU) × minutes (mins). Adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin-receptor-activating peptide (TRAP) were used as agonists.</div></div><div><h3>Results</h3><div>A total of 95 participants completed the trial. After 26 weeks, no significant differences were observed between the colchicine and placebo groups in platelet aggregation induced by ADP (ΔADP-aggregation: 49, 95 % CI: −15;113 AU x mins, <em>p</em> = 0.08), AA (ΔAA-aggregation: −4, 95 % CI: −24;16 %, <em>p</em> = 0.69), or TRAP (ΔTRAP-aggregation: −3, 95 % CI: −11;4 %, <em>p</em> = 0.39). Similarly, no between-group differences were found in platelet parameters, including platelet count mean platelet volume, and immature platelet fraction.</div></div><div><h3>Conclusions</h3><div>Low-dose colchicine did not significantly alter platelet aggregation or platelet activation indices in patients with type 2 diabetes. These findings suggest that colchicine's cardioprotective effects are not mediated through direct effects on platelet function.</div></div><div><h3>Clinical trial registration information</h3><div>EudraCT-no.: 2021-003525-30</div><div>Link: <span><span>https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003525-30/DK</span><svg><path></path></svg></span></div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109141"},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144704248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's response to the Letter to the Editor “Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy”","authors":"Shubham Agarwal ,&nbsp;F.N.U. Sidra ,&nbsp;Ildiko Lingvay","doi":"10.1016/j.jdiacomp.2025.109143","DOIUrl":"10.1016/j.jdiacomp.2025.109143","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109143"},"PeriodicalIF":3.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of time in range and glycemic risk index with insulin resistance and diabetic kidney disease in patients with type 2 diabetes","authors":"Zhe Yang ,&nbsp;Baozhen Zheng ,&nbsp;Guojing Luo ,&nbsp;Xiaoyan Xin ,&nbsp;Hongyun Lu","doi":"10.1016/j.jdiacomp.2025.109140","DOIUrl":"10.1016/j.jdiacomp.2025.109140","url":null,"abstract":"<div><h3>Aims</h3><div>Effective glycemic control is essential for preventing complications and improving quality of life in patients with type 2 diabetes mellitus (T2DM). Identifying reliable glycemic indicators for the assessment of islet function and renal complications remains a major challenge in diabetology. Time in Range (TIR) and Glycemia Risk Index (GRI), two continuous glucose monitoring (CGM)-based metrics, have recently emerged as potential tools for assessing glycemic control beyond HbA1c. This study aims to assess the predictive value of TIR and GRI for islet function impairment and diabetic kidney disease (DKD) in patients with T2DM.</div></div><div><h3>Methods</h3><div>A retrospective analysis of a total of 422 patients with T2DM was performed, who were admitted to Zhuhai People's Hospital between January 2021 and December 2022. Continuous glucose monitoring (CGM) data were collected to get TIR and GRI. Additionally, the C-peptide release, random urine biochemistry analysis, and C-reactive protein (CRP) were obtained to calculate HOMA-IR, HOMA-β, ISIstumvoll index, Stumvoll 1-phase and 2-phase index, and insulin resistance. The Urinary Albumin/Creatinine Ratio (UACR) was ascertained as a diagnostic marker of DKD.</div></div><div><h3>Results</h3><div>TIR and GRI demonstrated significant correlations with HOMA-IR, HOMA-β, and UACR; however, CRP exhibited a limited correlation with HOMA-IR and UACR. After adjustment for potential confounding factors, the odds ratios (ORs) for pancreatic β-cell function were: TIR 0.174 (95 % CI 0.051–0.592), GRI 1.010 (95 % CI 1.001–1.020). For DKD: TIR 0.182 (95 % CI 0.052–0.639), GRI 1.017 (95 % CI 1.007–1.027). TIR levels of 71 %–85 % and 41 %–70 % were associated with a 4.763-fold and 5.079-fold higher risk of insulin resistance, respectively, compared with TIR &gt; 85 %. Similarly, GRI levels of 21–30, 31–45, and 46–100 were associated with 2.553-fold, 2.597-fold, and 3.394-fold increases in insulin resistance risk compared with GRI ≤20. Despite excluding CRP, TIR and GRI differences in DKD and islet function were significant (<em>P</em> &lt; 0.05). In the regression analysis of DKD and islet function, excluding the CRP, TIR and GRI groups, the differences remained statistically significant (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>TIR was identified as a protective factor for pancreatic β-cell function, while GRI was associated with an increased risk of dysfunction. Furthermore, longer disease duration, higher HbA1c, elevated BMI, high GRI, and low TIR were associated with increased insulin resistance. A higher GRI and lower TIR also contributed to an elevated risk of DKD.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109140"},"PeriodicalIF":3.1,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor regarding “High rate of complications in a real-world cohort of youth with T2D: A multicenter analysis”","authors":"Risa M. Wolf ,&nbsp;Roomasa Channa ,&nbsp;Amy S. Shah","doi":"10.1016/j.jdiacomp.2025.109138","DOIUrl":"10.1016/j.jdiacomp.2025.109138","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109138"},"PeriodicalIF":3.1,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between relative fat mass and coronary artery calcification in patients with type 2 diabetes","authors":"Jingjing Ye ,&nbsp;Yu Qin ,&nbsp;Li Zhao ,&nbsp;Ling Yang ,&nbsp;Guoyue Yuan ,&nbsp;Meiqing Dai ,&nbsp;Shaohua Wang","doi":"10.1016/j.jdiacomp.2025.109133","DOIUrl":"10.1016/j.jdiacomp.2025.109133","url":null,"abstract":"<div><h3>Aims</h3><div>Relative fat mass (RFM) is a promising tool for identifying individuals with obesity-related health risks. Given the unclear correlation, we aimed to investigate the association between RFM and coronary artery calcification (CAC) in individuals with T2DM.</div></div><div><h3>Methods</h3><div>We included hospitalized individuals aged 20–80 years with T2DM (<em>n</em> = 278) in this single-center cross-sectional study. We explored the correlation between RFM and the CAC score (CACS), mechanisms underlying the association between RFM and CAC, and prediction models of coronary artery stenosis (CAS).</div></div><div><h3>Results</h3><div>Compared to the non-CAC group, the CAC group had a higher RFM. The CACS and RFM were positively correlated. The RFM independently increased the risk of CAC in individuals with T2DM. Using RFM to predict CAC resulted in an area under the curve of 0.598 (95 % CI [0.531–0.664], <em>p</em> &lt; 0.01); RFM was not inferior to visceral fat area for predicting CAC. Insulin resistance, systolic blood pressure, and estimated glomerular filtration rate mediated the association between RFM and CAS with proportions of 9.38 %, 18.82 %, and 11.36 %, respectively.</div></div><div><h3>Conclusions</h3><div>RFM was associated with CAC in individuals with T2DM. Given its potential role in predicting cardiovascular complications, incorporating RFM into clinical practice may facilitate the prevention and management of cardiovascular complications in T2DM.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109133"},"PeriodicalIF":2.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144696499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?","authors":"Roma-Wilson Maria Aurora ,&nbsp;Pozzilli Paolo","doi":"10.1016/j.jdiacomp.2025.109132","DOIUrl":"10.1016/j.jdiacomp.2025.109132","url":null,"abstract":"<div><div>Type 1 diabetes (T1D) is a heterogeneous autoimmune disease with multiple endotypes, each demonstrating distinct clinical and immunological characteristics. Teplizumab, an anti-CD3 monoclonal antibody, has emerged as a promising immunomodulatory therapy capable of delaying the progression of T1D in individuals with stage 2 disease. However, variability in therapeutic response suggests that certain endotypes may derive greater benefit from treatment. This review evaluates the suitability of different T1D endotypes (T1DE) for teplizumab prevention trials, with a particular focus on early-onset T1DE1 and T1DE2.</div><div>Clinical trials demonstrate that individuals under 15 years of age, who demonstrate the highest immune activity, marked by aggressive T-cell infiltration and rapid pancreatic β-cell destruction, experience the most significant delay in disease progression following teplizumab treatment, highlighting the importance of early intervention. Furthermore, shifting individuals from the rapidly progressing T1DE1 trajectory to the more gradual T1DE2 course may extend functional insulin production and improve long-term metabolic outcomes.</div><div>This paper underscores the need for expanded endotype-specific prevention trials and optimised screening protocols to identify high-risk individuals at the earliest stage. Future research should explore teplizumab's efficacy in younger populations and refine predictive biomarkers to enhance personalised intervention strategies in T1D management.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109132"},"PeriodicalIF":2.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144665578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BETTER sleep: Sleep quality among adults living with type 1 diabetes in Canada","authors":"Lydi-Anne Vézina-Im ,&nbsp;Anne-Frédérique Turcotte ,&nbsp;Virginie Messier ,&nbsp;Stéphane Turcotte ,&nbsp;Ariane Brossard ,&nbsp;Jacques Pelletier ,&nbsp;Tara Nassar ,&nbsp;Rémi Rabasa-Lhoret ,&nbsp;Anne-Sophie Brazeau","doi":"10.1016/j.jdiacomp.2025.109137","DOIUrl":"10.1016/j.jdiacomp.2025.109137","url":null,"abstract":"<div><h3>Aims</h3><div>Identify correlates of poor sleep quality among people living with type 1 diabetes (PwT1D).</div></div><div><h3>Methods</h3><div>Data were extracted from the BETTER Registry. Sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI). Sociodemographic characteristics (age, biological sex, education, income, ethnicity, body mass index); diabetes-related (diabetes duration, glucose monitoring method, treatment type, hypoglycemia awareness); psychological (fear of hypoglycemia, diabetes-related distress and stigma, depression, social support); and behavioral (snacking before bedtime, caffeine, alcohol and cannabis use, moderate-to-vigorous physical activity [MVPA]) variables were tested in multivariate logistic regression analyses for their association with poor sleep quality (PSQI &gt;5).</div></div><div><h3>Results</h3><div>A total of 1322 PwT1D (mean age: 45.0 ± 15.0 years; 66.9 % female) had sleep data. The mean PSQI score was 6.0 ± 3.4 and 47.3 % had poor sleep quality. Being female (OR = 1.422; 95 % CI: 1.080–1.873), with overweight/obesity (OR = 1.376; 95 % CI: 1.067–1.775), greater fear of hypoglycemia (OR = 1.016; 95 % CI: 1.008–1.023), having moderate-to-severe depression (OR = 6.160; 95 % CI: 4.250–8.929), always snacking before bedtime (OR = 1.706; 95 % CI: 1.124–2.590), using cannabis (OR = 1.578; 95 % CI: 1.152–2.161), and accumulating &lt;150 min/week of MVPA (OR = 1.563; 95 % CI: 1.107–2.203) were correlates of poor sleep quality.</div></div><div><h3>Conclusions</h3><div>Many PwT1D have poor sleep quality, and their sleep is associated with various sociodemographic, psychological, and behavioral factors.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109137"},"PeriodicalIF":2.9,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144662638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated small dense low-density lipoprotein-cholesterol as a risk factor for lower extremity arterial disease in patients with type 2 diabetes mellitus","authors":"Delu Zheng ,&nbsp;Chenli Cui","doi":"10.1016/j.jdiacomp.2025.109136","DOIUrl":"10.1016/j.jdiacomp.2025.109136","url":null,"abstract":"<div><h3>Aims</h3><div>Small dense low-density lipoprotein-cholesterol (sdLDL-C) is an emerging atherogenic lipid marker, but its association with lower extremity arterial disease (LEAD) in type 2 diabetes mellitus (T2DM) remains underexplored. This study aimed to evaluate whether sdLDL-C independently predicts LEAD risk in T2DM patients.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted with 47 healthy controls, 66 T2DM patients, and 120 patients with both T2DM and LEAD. Biochemical markers were compared, and predictive value was assessed using a receiver operating characteristic (ROC) curve. Multivariable logistic regression analyzed the association between sdLDL-C and LEAD after adjusting for conventional risk factors.</div></div><div><h3>Results</h3><div>sdLDL-C levels were significantly higher in T2DM patients compared to healthy controls (1.06 [0.88–1.25] vs. 0.77 [0.43–1.04] mmol/L, <em>P</em> &lt; 0.001), and even higher in those with both T2DM and LEAD (1.33 [1.17–1.56] mmol/L). sdLDL-C levels were associated with the severity of LEAD and positively correlated with fasting blood glucose, fasting C-peptide, hemoglobin A1c, total cholesterol, triglycerides, LDL-C, apolipoprotein B, and body mass index. ROC analysis yielded an area under the curve of 0.765 (95 % CI: 0.692–0.838, <em>P</em> &lt; 0.0001), indicating good predictive value of sdLDL-C for LEAD in T2DM. Multivariable logistic regression identified sdLDL-C (OR = 7.881, 95%CI: 1.368–45.394, <em>P</em> = 0.021), fasting C-peptide, hemoglobin A1c, apolipoprotein B, diabetes duration, and sedentary lifestyle as significant risk factors for LEAD in T2DM patients.</div></div><div><h3>Conclusions</h3><div>Elevated sdLDL-C is independently associated with LEAD in T2DM patients and outperforms conventional LDL-C in risk stratification. sdLDL-C may serve as a valuable biomarker for early detection of LEAD in this high-risk population.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109136"},"PeriodicalIF":2.9,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of fenofibrate in diabetic retinopathy: Narrative review","authors":"Harsha A. Dissanayake ,&nbsp;Christine A. Kiire ,&nbsp;David Preiss ,&nbsp;Garry D. Tan","doi":"10.1016/j.jdiacomp.2025.109135","DOIUrl":"10.1016/j.jdiacomp.2025.109135","url":null,"abstract":"<div><div>Diabetic retinopathy (DR) is a leading cause of blindness despite advances in treatment and there remains an unmet need for low-cost interventions to prevent and slow the progression of DR. Fenofibrate has shown promise as a useful adjunct in DR management and is licensed for use in the treatment of DR in a few countries. However, the data supporting the use of fenofibrate for the treatment of DR emerged from subsidiary analyses of the FIELD, ACCORD-LIPID and its sub-study ACCORD-EYE trials, which were primarily designed to evaluate cardiovascular outcomes. The recently concluded LENS trial, designed to evaluate the effect of fenofibrate on progression of DR, has shown clear evidence of benefit over medium-term follow-up (i.e., 4–5 years), and confirmed its safety in people with type 1 or type 2 diabetes. These benefits appear to be independent of fenofibrate's lipid lowering effects and are more likely to be mediated via its direct effects on the eye. In this narrative review on the use of fenofibrate in the treatment of DR, we summarise the possible mechanisms of action, existing evidence from randomised trials, and implications for clinical practice and research.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109135"},"PeriodicalIF":2.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor “Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy”","authors":"Joaquín Borrás-Blasco ,&nbsp;Alejandro Valcuende-Rosique ,&nbsp;Silvia Cornejo-Uixeda","doi":"10.1016/j.jdiacomp.2025.109134","DOIUrl":"10.1016/j.jdiacomp.2025.109134","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109134"},"PeriodicalIF":3.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}